Central Nervous System News and Research

RSS

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

A breakthrough in stroke research identifying the potential reversibility of chronic neurologic disability in stroke survivors has published today. In the February 1, 2011 issue of the journal CNS Drugs the first human results of a new method of targeting chronic brain inflammation years after stroke are reported.

2 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

New study sheds further light on stroke recovery process

Most people who survive a stroke recover some degree of their motor, sensory and cognitive functions over the following months and years. This recovery is commonly believed to reflect a reorganisation of the central nervous system that occurs after brain damage. Now a new study, published in the February 2011 issue of Elsevier's Cortex, sheds further light on the recovery process through its effect on language skills.

1 Feb 2011

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

AVANIR Pharmaceuticals, Inc. today announced that NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA).

1 Feb 2011

Histamine can be an important molecule to develop new treatments for MS

If you think histamines are your nemesis during allergy season, here's something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an important molecule to developing new treatments for multiple sclerosis.

1 Feb 2011

Oragenics to commence second phase 1 clinical trial for SMaRT Replacement Therapy

Florida-based biopharmaceutical company Oragenics, today announced its intention to commence a second phase 1 clinical trial of SMaRT Replacement Therapy.

31 Jan 2011

Taxol reduces cell regeneration obstacles after spinal cord injury: Scientists

After a spinal cord injury a number of factors impede the regeneration of nerve cells. Two of the most important of these factors are the destabilization of the cytoskeleton and the development of scar tissue.

29 Jan 2011

Adeona to sell 2.85 million common stock at $1.40 per share

Adeona Pharmaceuticals, a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement for the sale of approximately 2.85 million shares of its common stock at $1.40 per share to two new institutional investors in a registered direct offering for $4 million in gross proceeds.

29 Jan 2011

LFA launches new nationwide education series for people with lupus

The Lupus Foundation of America has launched a new nationwide education series, Lupus: Learn from the Experts, designed to provide people with lupus essential information about living with lupus from some of the world's leading lupus experts. The program is a series of teleconferences hosted by a lupus expert, and will cover a wide variety of topics important to people with lupus, including disability, kidney involvement, and clinical trials.

29 Jan 2011

Research provides new clues for compulsive behavior, cognitive defects linked with LND

Research from the University of California, San Diego School of Medicine provides new clues for the compulsive behavior and cognitive defects associated with a rare childhood neurological disease called Lesch-Nyhan Disease.

29 Jan 2011

Taxol drug promotes regeneration of nerve cells in CNS after spinal cord injury: Study

In a study published today in Science, a global research team reports that the cancer drug Taxol promotes the regeneration of injured nerve cells in the central nervous system after spinal cord injury.

28 Jan 2011

New molecular player responsible for regulation of appetite and metabolism

A study by researchers at Mayo Clinic's campus in Florida and Washington University School of Medicine adds a new twist to the body of evidence suggesting human obesity is due in part to genetic factors. While studying hormone receptors in laboratory mice, neuroscientists identified a new molecular player responsible for the regulation of appetite and metabolism.

28 Jan 2011

Protein Erk necessary for nerve fibers to be wrapped with myelin

Researchers at the University of North Carolina at Chapel Hill have pinpointed a crucial function for a key player in the development of the nervous system. They found that this player - a protein called Erk - is necessary for nerve fibers to be wrapped with an insulating substance called myelin, which allows messages to be sent from the brain to the peripheral limbs and back again.

28 Jan 2011

CHUV university hospital to implement OpenTrust Crypt'n'Share for secure exchange of sensitive information

OpenTrust, the Next-Gen IT security software publisher, today announced that the CHUV university hospital in Lausanne has chosen to use OpenTrust Crypt'n'Share to securely exchange sensitive information throughout the establishment.

27 Jan 2011

Researchers discover new sensory neurons that mediate BP and metabolism regulation in liver

For 60 years, scientists have puzzled over the possibility of a hepatic osmoreceptor that influences blood pressure regulation. Now, researchers of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch, the Experimental and Clinical Research Center of the MDC and Charit- and the Hannover Medical School appear to have made a breakthrough discovery.

27 Jan 2011

Researchers find food-borne bacteria can cause difficult-to-treat heart infections

Researchers at the University of Illinois at Chicago College of Medicine have found that particular strains of a food-borne bacteria are able to invade the heart, leading to serious and difficult-to-treat heart infections.

27 Jan 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

SNM commends FDA Advisory Committee recommendation for florbetapir approval

The Society of Nuclear Medicine (SNM) commends the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee on its recent recommendation for conditional approval of a new imaging agent, florbetapir.

25 Jan 2011

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011

Bayer's gadobutrol injection for CNS imaging receives FDA Advisory Committee approval

Bayer HealthCare Pharmaceuticals Inc. announced today that the Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously that clinical trial and postmarketing data for gadobutrol injection, a macrocyclic 1.0 molar gadolinium-based contrast agent (GBCA), support approval of the product for proposed use in diagnostic magnetic resonance imaging (MRI) in adults and children.

24 Jan 2011

Central Nervous System News and Research

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

New study sheds further light on stroke recovery process

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

Histamine can be an important molecule to develop new treatments for MS

Oragenics to commence second phase 1 clinical trial for SMaRT Replacement Therapy

Taxol reduces cell regeneration obstacles after spinal cord injury: Scientists

Adeona to sell 2.85 million common stock at $1.40 per share

LFA launches new nationwide education series for people with lupus

Research provides new clues for compulsive behavior, cognitive defects linked with LND

Taxol drug promotes regeneration of nerve cells in CNS after spinal cord injury: Study

New molecular player responsible for regulation of appetite and metabolism

Protein Erk necessary for nerve fibers to be wrapped with myelin

CHUV university hospital to implement OpenTrust Crypt'n'Share for secure exchange of sensitive information

Researchers discover new sensory neurons that mediate BP and metabolism regulation in liver

Researchers find food-borne bacteria can cause difficult-to-treat heart infections

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

SNM commends FDA Advisory Committee recommendation for florbetapir approval

FDA approves Clinical Data's Viibryd for major depressive disorder

Bayer's gadobutrol injection for CNS imaging receives FDA Advisory Committee approval

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News